TITLE

Accelerated phase CML patients benefitted from nilotinib

AUTHOR(S)
Forman, Stephen
PUB. DATE
March 2008
SOURCE
Hem/Onc Today;3/10/2008, Vol. 9 Issue 4, p28
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on studies that examined the effectivity of the novel oral tyrosine kinase inhibitor nilotinib (Tasigna, Novartis) among patients with accelerated phase chronic myelogenous leukemia (CML-AP) and resistance or intolerance to imatinib (Gleevac, Novartis). One study found nilotinib to be effective among patients with CML-CP and resistance or intolerance to imatinib.
ACCESSION #
31672193

 

Related Articles

  • Feature Analysis Chronic leukemias: different forms, different problems, different solutions.  // PharmaWatch: Monthly Review;Jan2006, Vol. 5 Issue 1, p13 

    This article presents information on the diagnosis and treatment of different types of chronic leukemia. Treatment of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) presents unique problems. Novartis' Gleevec is being used in the treatment of CML since December 2002....

  • Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL. Breccia, Massimo; Alimena, Giuliana // Current Drug Targets;Jun2009, Vol. 10 Issue 6, p530 

    Imatinib mesylate is currently the standard therapy for chronic myeloid leukemia (CML) patients. Despite the remarkable results achieved with imatinib, the emergence of resistance to this drug has become a significant problem. Several strategies have been developed to overcome imatinib...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Tolomeo, Manlio; Dieli, Francesco; Gebbia, Nicola; Simoni, Daniele // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 8, p853 

    Imatinib mesylate (Gleevec) is a drug unique for the treatment of certain forms of cancer. It works by targeting, and turning off, specific tyrosine kinase proteins that cause the uncontrolled cell growth and the inhibition of apoptosis in cancer cells. Imatinib was designed on the basis of the...

  • New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms. Schenone, S.; Brullo, C.; Botta, M. // Current Medicinal Chemistry;May2010, Vol. 17 Issue 13, p1220 

    Resistance to the Bcr-Ab1 inhibitors approved for the treatment of chronic myeloid leukaemia (CML) may arise from different mechanisms, including Bcr-Ab1 amino acid mutations, gene amplification and mechanisms independent of Bcr-Ab1. The T3151 mutation at the gatekeeper residue is very frequent...

  • imatinib.  // Royal Society of Medicine: Medicines;2002, p297 

    This article provides information on the drug imatinib. It is a recently introduced protein-tyrosine kinase inhibitor cytotoxic drug, which is used as an anticancer treatment for myeloid leukemia. It works by interference with the action of an abnormal form of an enzyme in the body that can...

  • Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Fu, Dan; Zhou, Jing; Zhu, Wenjing Suzanne; Manley, Paul W.; Wang, Y. Karen; Hood, Tami; Wylie, Andrew; Xie, X. Sunney // Nature Chemistry;Jul2014, Vol. 6 Issue 7, p614 

    ABL1 tyrosine-kinase inhibitors (TKI) are front-line therapy for chronic myelogenous leukaemia and are among the best-known examples of targeted cancer therapeutics. However, the dynamic uptake into cells of TKIs of low molecular weight and their intracellular behaviour is unknown because of the...

  • Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Gurrea Salas, David; Glauche, Ingmar; Tauer, Josephine; Thiede, Christian; Suttorp, Meinolf // Annals of Hematology;Aug2015, Vol. 94 Issue 8, p1363 

    In contrast to adult medicine, specific scoring systems predicting the treatment response for an individual pediatric patient (pt) with chronic myeloid leukemia (CML) have not yet been defined. We evaluated to what extend prognostic scores as described for adults (e.g., Sokal, Hasford, EUTOS...

  • Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor. Kimura, Shinya; Niwa, Tomoko; Hirabayashi, Kazuko; Maekawa, Taira // Cancer Chemotherapy & Pharmacology. Supplement;Dec2006, Vol. 58, p55 

    Imatinib mesylate (Gleevecâ„¢) has improved the treatment of Bcr-Abl-positive leukemia. However, resistance is often reported in patients with advanced-stage disease. Chemical modifications of imatinib made with the guidance of molecular modeling have yielded several promising compounds that...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics